<DOC>
	<DOCNO>NCT02790138</DOCNO>
	<brief_summary>The purpose study assess efficacy safety vedolizumab intravenous ( IV ) participant proctocolectomy ileal pouch anal anastomosis ulcerative colitis ( UC ) develop chronic recurrent pouchitis , require continuous antibiotic treatment .</brief_summary>
	<brief_title>Phase 4 Study Evaluate Efficacy Safety Vedolizumab Treatment Chronic Pouchitis</brief_title>
	<detailed_description>Vedolizumab test treat people chronic pouchitis . This study look heal inflammation ileal pouch people take vedolizumab The study enroll approximately 200 patient . Participants randomly assign one two treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Vedolizumab 300 mg IV - Placebo All participant receive intravenous infusion Weeks 0 , 2 , 6 , 14 , 22 , 30 along concomitant antibiotic treatment ciprofloxacin 500 mg twice daily Week 4 . This multicenter trial conduct North America Europe . The overall time participate study 34 week . Participants make multiple visit clinic , plus final visit 18 week last dose study drug safety follow-up assessment . Participants also participate long-term safety follow-up , phone , 6 month last dose study drug ( Week 56 ) .</detailed_description>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Pouchitis</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 4 . Has history ileal pouch anal anastomosis ( IPAA ) ulcerative colitis ( UC ) complete least 1 year prior Screening Visit . 5 . Has pouchitis chronic recurrent , define modify Pouchitis Disease Activity Index ( mPDAI ) ≥5 &gt; 2 episode within 1 year Screening Visit require longterm continuous lowdose antibiotic therapy take daily ongoing basis ( eg , ciprofloxacin 250500 mg/day metronidazole 500 mg/day take several week month time ) frequent pulse antibiotic therapy . 6 . Agrees stop antibiotic therapy Day 1 study switch ciprofloxacin Week 4 study . ( Additional course ciprofloxacin allow , need , flare Week 14 . ) 7 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 18 week last dose . 8 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study 18 week last dose . Gastrointestinal Exclusion Criteria 1 . Has Crohn 's disease ( CD ) , CD pouch . 2 . Has irritable pouch syndrome ( IPS ) . 3 . Has cuffitis . 4 . Has mechanical complication pouch ( eg , pouch stricture pouch fistula ) . 5 . Currently require planned surgical intervention UC study . Infectious Disease Exclusion Criteria 1 . Has evidence active infection ( eg , sepsis , cytomegalovirus , listeriosis ) Screening . 2 . Has active latent tuberculosis ( TB ) , regardless treatment history , evidence following : 1 . History TB . 2 . A diagnostic TB test perform Screening positive , define : 1 . A positive QuantiFERON test 2 successive indeterminate QuantiFERON test OR 2 . A tuberculin skin test reaction ≥10 mm ( ≥5 mm participant receive equivalent &gt; 15 mg/day prednisone ) . OR Chest Xray within 3 month prior Week 0 , suspicious pulmonary TB , positive 2 successive indeterminate QuantiFERON test within 30 day prior Screening Screening Period . 3 . Has positive test result hepatitis B surface antigen ( HBsAg ) , antibody hepatitis C virus ( antiHCV ) , Screening know history human immunodeficiency virus infection ( eg , common variable immunodeficiency , human immunodeficiency virus [ HIV ] infection , organ transplantation ) . General Exclusion Criteria 1 . Has prior exposure vedolizumab , natalizumab , efalizumab , rituximab , etrolizumab , anti mucosal addressin cell adhesion molecule1 ( MAdCAM1 ) therapy . 2 . Has history hypersensitivity allergy vedolizumab component . 3 . Has allergies and/or contraindication ciprofloxacin ( include interact drug tizanidine ) . 4 . Is take , take , required take exclude medication . 5 . Has receive investigational approve biologic biosimilar agent within 60 day 5 halflives randomization ( whichever longer ) . 6 . Has receive investigational nonbiologic therapy within 30 5 halflives day prior randomization ( ever longer ) . 7 . Has receive approve nonbiologic therapy ( include 5aminosalicylate [ 5ASA ] , corticosteroid , azathioprine , 6mercaptopurine [ 6MP ] , etc . ) investigational protocol within 30 day 5 half life prior randomization ( ever longer ) . 8 . Has receive live vaccination within 30 day prior randomization . 9 . Has positive progressive multifocal leukoencephalopathy ( PML ) subjective symptom checklist Screening . 10 . Has history tendon rupture rupture disorder relate quinolone administration 11 . Has kidney , heart , lung transplant . 12 . Has myasthenia gravis , peripheral neuropathy , QT prolongation , history seizure . 13 . Has history malignancy , except follow : adequatelytreated nonmetastatic basal cell skin cancer ; squamous cell skin cancer adequately treat recur least 1 year prior Screening visit ; history cervical carcinoma situ adequately treat recur least 3 year prior Screening . Participants remote history malignancy ( eg , &gt; 10 year since completion curative therapy without recurrence ) consider base nature malignancy therapy receive must discuss sponsor casebycase basis prior enrollment . 14 . Has history major neurological disorder , include stroke , multiple sclerosis , brain tumor , demyelinate , neurodegenerative disease . 15 . Has condition , opinion investigator , may interfere participant 's ability comply study procedure . 16 . Has unstable uncontrolled cardiovascular , pulmonary , hepatic , renal , gastrointestinal ( GI ) , genitourinary , hematological , coagulation , immunological , endocrine/metabolic , neurologic , medical disorder , opinion investigator , would confound study result compromise participant safety . 17 . Has follow laboratory abnormality Screening Period : 1 . Hemoglobin level &lt; 8 g/dL . 2 . White blood cell ( WBC ) count &lt; 3 × 10^9/L . 3 . Lymphocyte count &lt; 0.5 × 10^9/L . 4 . Platelet count &lt; 100 × 10^9/L &gt; 1200 × 10^9/L . 5 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 × upper limit normal ( ULN ) . 6 . Alkaline phosphatase &gt; 3 × ULN . 7 . Serum creatinine &gt; 2 × ULN . 18 . If female , participant pregnant lactate intend become pregnant nurse , , within 18 week last dose study medication ; intend donate ova time period . 19 . If male , participant intend donate sperm father child course study 18 week last dose study medication . 20 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 21 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior Visit 1 . 22 . The subject glucose6phosphate dehydrognnase ( G6PD ) deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>